The Wegovy prescribing information is where weight-related eligibility lives: in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition
Many factors contribute to these results, most notably where a patient starts, how long they stay on the medication, and how compliant they are with controlling external factors like activity/exercise and stress management/sleep
Key Background Manufactured by Novo Nordisk, both Ozempic and Wegovy are once-weekly injections used to regulate blood sugar in type 2 diabetics
Below is an overview of how the two compare: Mechanism of Action: Retatrutide: Triple agonist (GLP-1, GIP, glucagon) Zepbound: Dual agonist (GLP-1, GIP) Developer: Retatrutide: Eli Lilly and Company (investigational) Zepbound: Eli Lilly and Company (approved) Regulatory Status: Retatrutide: Phase III clinical development Zepbound: FDA-approved for obesity, obstructive sleep apnea Weight Loss Efficacy: Retatrutide: Up to ~28.7% (68 weeks
:max_bytes(150000):strip_icc()/what-causes-sulfur-burps-4587735-01-dda6a0c753b044139e79f6bb9cc2cc40.png)
